Table 1.
Cohort characteristics
| Level | Value | |
|---|---|---|
| n | 180 | |
| Diagnosis [n (%)] | CN | 100 (55.6) |
| SCD | 80 (44.4) | |
| Age [mean (sd)] | 73.01 (5.29) | |
| Sex [n (%)] | Male | 69 (38.3) |
| Female | 111 (61.7) | |
| Education [mean (sd)] | 11.90 (3.32) | |
| APOE ε4 alleles [n (%)] | 0 | 119 (66.1) |
| 1 | 51 (28.3) | |
| 2 | 10 (5.5) | |
| Aβ PET, SUVR [mean (sd)] | 0.73 (0.15) | |
| Aβ PET, status [n (%)] | Normal | 128 (71.1) |
| Abnormal | 52 (28.9) | |
| PACC, baseline [mean (sd)] | −0.13 (3.63) | |
| Plasma Aβ42/Aβ40 [mean (sd)] | 0.13 (0.01) | |
| Plasma P-tau217 [mean (sd)] | 0.17 (0.14) | |
| Plasma NfL [mean (sd)] | 21.33 (9.70) | |
| Plasma GFAP [mean (sd)] | 1247.75 (621.75) |
This table describes the cohort used for analysis. All continuous values are reported as mean and standard deviation while all categorical values are reported as count and percentage.
CN, cognitively normal; GFAP, glial fibrillary acidic protein; PACC, preclinical Alzheimer cognitive composite; SCD, subjective cognitive decline.